Confronto

Cerebrolysin vs. Melanotan II

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

96889-70-6

121062-08-6

Peso molecolare

nessun dato

1024.18 g/mol

Emivita

nessun dato

1 h

Sequenza

nessun dato

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2

Meccanismo d'azione

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Melanotan II

Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Cerebrolysin	Melanotan II
Austria	Su prescrizione	—
Australia	—	Vietato
CN	Su prescrizione	—
Germania	Non chiaro	Non approvato
Regno Unito	—	Vietato
RU	Su prescrizione	—
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Cerebrolysin and Melanotan II?: Cerebrolysin is classified as "Ricerca (altro)", while Melanotan II is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Melanotan II?: The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Melanotan II in Germany and the United States?: Germania: Cerebrolysin — Non chiaro, Melanotan II — Non approvato. Stati Uniti: Cerebrolysin — Non approvato, Melanotan II — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Melanotan II

Austria

Su prescrizione

—

Australia

—

Vietato

Su prescrizione

—

Germania

Non chiaro

Non approvato

Regno Unito

—

Vietato

Su prescrizione

—

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Cerebrolysin and Melanotan II?

Cerebrolysin is classified as "Ricerca (altro)", while Melanotan II is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Melanotan II?

The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Melanotan II in Germany and the United States?

Germania: Cerebrolysin — Non chiaro, Melanotan II — Non approvato. Stati Uniti: Cerebrolysin — Non approvato, Melanotan II — Non approvato. These are factual summaries with source and review date on the individual pages.